OVERVIEW

The program will discuss key clinical trial findings presented at the European Society of Cardiology Congress. The program format will engage participants in an interactive discussion regarding trial result implications.

Topics:

• DELIVER – Does dapagliflozin improve outcomes in HFpEF? PERSPECTIVE – Does sacubitril/valsartan affect cognitive function  in heart failure? 
• PACIFIC Trials – What is the role of new factor Xia inhibitors in  stroke and ACS? 
• FOURIER OLE – What are the long-term safety data for PCSK9  inhibitors? 
• ALL-HEART – Does allopurinol improve cardiovascular  outcomes?  
• SECURE – Is there a role for a polypill in secondary prevention? And more! 

LEARNING OBJECTIVES

Following participation in this program, participants will be able  to: 

• Identify the clinical implications of the new data presented at ESC 2022 
• Examine where the data presented may impact clinical  practice guidelines 
• Apply the latest evidence-based strategies in clinical practice

For more information please visit the official event page.